Navigation Links
D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
Date:6/8/2009

REHOVOT, Israel, June 8 /PRNewswire/ -- D-Pharm announced today that its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients has been approved by the US Food and Drug Administration (FDA). D-Pharm plans to initiate the trial in the coming months, in over 100 clinical sites in North America, Europe, South Africa and Israel.

The forthcoming Phase III trial is a randomized, double blind, placebo-controlled study (study acronym MACSI: Membrane Activated Chelator Stroke Intervention). It is designed to compare the effect on ischemic stroke outcome between a placebo group and a group of patients treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. D-Pharm plans to enroll 770 moderate to severely affected ischemic stroke patients worldwide, with first patients expected to be recruited in Israel and South Africa.

Dr. Gilad Rosenberg, D-Pharm's VP Clinical Development commented, "The FDA's IND procedure involved review of the entire DP-b99 data set. Following 30 days for review of our IND application, the FDA has no further questions relating to DP-b99's CMC, preclinical and clinical data package. I'm very pleased that the Agency is satisfied with our data and we can move forward with this important study without delay."

Prior to the IND submission D-Pharm successfully completed the program outlined at the pre-IND meeting held with the FDA in January 2008. The program included additional toxicity studies, a drug interaction study with rtPA, and an interaction study with warfarin in healthy volunteers, as well as scale-up and optimization of the DP-b99 manufacturing process.

About DP-b99

DP-b99 is a unique neuroprotective drug that addresses an array of brain damaging processes occurring in stroke patients and emerged from D-Pharm's proprietary Membrane Activated Chelator (MAC) platform technolog
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. D-Pharm Secures Funding From Israels Chief Scientists Office
2. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
3. Yongye Biotechnology International Receives License to Manufacture Products
4. EarlySenses EverOn(TM) System Receives FDA Clearance and CE Mark Certification
5. Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners
6. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
7. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
8. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
9. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
10. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
11. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), ... royalty revenue from sales of Thalomid® during the ... $3.3 million. In addition, the Company anticipates ... for fiscal 2009. The difference in estimated ... be reflected in the fourth quarter financial results. ...
(Date:12/11/2009)... December 10, 2009 miRagen Therapeutics, Inc., a ... developing innovative microRNA-based therapeutics for cardiovascular and muscle ... that microRNA-206 (miR-206) plays a crucial role in ... Lou Gehrig,s disease) and in neuromuscular synaptic regeneration ... December 11 issue of the journal Science ...
(Date:12/11/2009)... HILL, MA (12/11/2009) Boston College researchers have observed ... the first time and successfully harvested the elusive charges ... improved solar power efficiency, the authors report in the ... , When light is captured in solar cells, it ... But in order to snare these charges, the electrons ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... American Academy of Pediatrics National Conference & ... ... Pa., Oct. 29 Tengion,Inc., a leader in regenerative medicine, announced ... American Academy of,Pediatrics (AAP) National Conference and Exhibition demonstrate the ability,of ...
... SAN MARCOS, Calif., Oct. 29 Cliniqa ... diagnostic products, is pleased to,announce the acquisition ... "Raichem" (San Diego, CA), a wholly owned ... is a manufacturer of clinical,diagnostic products focusing ...
... Repair Discussed at American Society of Plastic Surgeons ... ... the debut of NBC,s,"Bionic Woman," the notion of a bionic person ... getting closer to reality,as reconstructive plastic surgeons perform quality-of-life-enhancing,peripheral nerve surgeries ...
Other Biology Technology:Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2Creating the Bionic Woman: Making Nerves Spring Back to Life 2Creating the Bionic Woman: Making Nerves Spring Back to Life 3
(Date:12/11/2009)... professor of anthropology at the University of Arizona, has ... understand how violence shapes the health of those eking ... and her colleagues, research," Documenting the health consequences of ... A conceptual framework," is currently published in a special ... collaboration with the British medical journal the Lancet ...
(Date:12/11/2009)... edition of Springer,s classic reference and textbook Vogel and ... McKusick Leadership Award. The prize, which recognizes Professor Motulsky,s ... presented to him at the 59th Annual Meeting of ... 2009 in Honolulu, Hawaii. , Motulsky is Professor Emeritus ... Washington in Seattle. One of the founding giants of ...
(Date:12/11/2009)... lost a moderate amount of weight by eating less ... study at Washington University School of Medicine in St. ... in the Dec. 15, 2009, issue of the ... that weight loss led to improvement in four key ... in the study participants included decreased thickness of heart ...
Breaking Biology News(10 mins):UA-led study grapples with health effects of low-intensity warfare 2Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3From the glass to the brain in 6 minutes 8835 1From the glass to the brain in 6 minutes 8835 2Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 1Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 2Finding Raises Hope for Treating ALS 48916 1Finding Raises Hope for Treating ALS 48916 2
... the Biomedical Engineering Society (BMES) will launch a ... (CMBE) in March 2008. Springer is already ... Biomedical Engineering. , Cellular and Molecular Bioengineering ... of cellular and molecular bioengineering, thus advancing this ...
... A consortium of researchers led by the Genome Sequencing Center ... the completion of a draft sequence of the corn genome. ... partnership with the U.S. Department of Agriculture (USDA) and the ... to sequence the corn genome. The goal of the project ...
... Dr. Peter Glynn, a professor at the University of ... been selected to receive the 2007-2008 Provosts Award for ... pursuits, and provides the recipient with a cash award ... time Glynn, who received the award when it was ...
Other Biology News:Springer expands publishing partnership with the Biomedical Engineering Society 2All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3UM coral scientist Peter Glynn wins award for scholarly activity 2
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
Request Info...
... new Thermo Electron RapidStak provides valuable walk-away ... a unique buffer nest technology for parallel ... RapidStak provides fast, reliable automation for any ... walk-away confidence. The RapidStak can be set-up ...
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
Biology Products: